m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03573
 [1], [2]
Histone modification H3K27ac EP300 LINC01605 Indirect Enhancement m6A modification PLAU PLAU METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Urokinase-type plasminogen activator (PLAU)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone acetyltransferase p300 (P300) WRITER View Details
Regulated Target Histone H3 lysine 27 acetylation (H3K27ac) View Details
Downstream Gene LINC01605 View Details
Crosstalk Relationship Histone modification  →  m6A Enhancement
Crosstalk Mechanism histone modification indirectly regulates m6A modification through downstream signaling pathways
Crosstalk Summary LINC01605 was regulated by SMYD2-p300-mediated modifications of histone H3K4me3 as well as Histone H3 lysine 27 acetylation (H3K27ac). LINC01605 was found to bind to METTL3 and promote the m6A modification of SPTBN2 mRNA, thereby facilitating the translation of SPTBN2. METTL3 upregulated Urokinase-type plasminogen activator (PLAU) mRNA in an m6A-dependent manner, and then participated in MAPK/ERK pathway to promote angiogenesis and metastasis in CRC.
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Pathway Response MAPK signaling pathway hsa04010
Cell Process Cell proliferation and metastasis
Cell apoptosis
In-vitro Model
 HT29 Colon cancer Mus musculus CVCL_A8EZ
LoVo Colon adenocarcinoma Homo sapiens CVCL_0399
In-vivo Model 1 × 106 cells in 100 uL PBS (shMETTL3-1 or shNC) were respectively injected into each mouse through the tail vein. Pulmonary metastases were monitored after fourteen days using the imaging system (IVIS) Spectrum (PerkinElmer, USA).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Histone acetyltransferase p300 (P300) 2 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name CCS1477 Phase 1/2 [3]
Synonyms
CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 134457551
TTD: DIY4C2
 Compound Name FT-7051 Phase 1 [4]
MOA Inhibitor
External Link
TTD: DT8IL6
Urokinase-type plasminogen activator (PLAU) 42 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Pro-urokinase Approved [5]
Synonyms
Thrombolyse (TN)
    Click to Show/Hide
MOA Modulator
External Link
TTD: D03VNX
 Compound Name Urokinase Approved [6]
MOA Modulator
External Link
TTD: D0E8UO
 Compound Name PAI-1 Phase 4 [7]
Synonyms
PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3246941
TTD: D03ZJE
DrugBank: DB08324
 Compound Name Amediplase Phase 3 [8]
Synonyms
Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol
    Click to Show/Hide
MOA Activator
External Link
CID: 154656
TTD: D0G6ZG
 Compound Name Upamostat Phase 2 [9]
Synonyms
WX-671
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 410 nM
External Link
CID: 9830667
TTD: D03KGH
 Compound Name Saruplase Phase 2 [10]
Synonyms
Rescupase; CG-4509; PUK, Grunenthal; Pro-urokinase, Grunenthal; Rscu-PA, Grunenthal
    Click to Show/Hide
MOA Activator
External Link
TTD: D0G5UW
 Compound Name HTU-PA Phase 1/2 [11]
Synonyms
Human tissue urokinase type plasminogen activator, Global Biotech
    Click to Show/Hide
MOA Activator
External Link
TTD: D01HHJ
 Compound Name PMID18163548C4 Clinical trial [12]
Synonyms
7IN; 1vja; AC1L9MNX; GTPL6545; BDBM50231520; US8476306, 6.12
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 20 nM
External Link
CID: 449051
TTD: D00EPS
 Compound Name UK-356202 Clinical trial [13]
Synonyms
compound 13j [PMID: 15149680]; UK-356,202
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 37 nM
External Link
CID: 9885167
TTD: D0G0YZ
 Compound Name PAI-2 Discontinued in Phase 2 [14]
Synonyms
N-Butyryl-DL-homoserine lactone; N-butanoyl-lhomoserine lactone; N-(2-oxooxolan-3-yl)butanamide; N-(2-oxotetrahydrofuran-3-yl)butanamide; N-Butyrylhomoserine lactone; 98426-48-3; N-(2-Oxotetrahydro-3-furanyl)butanamide; AC1L9ENE; SCHEMBL787006; Homoserine lactone, N-butanoyl-; N-Butanoyl-DL-homoserine lactone; VFFNZZXXTGXBOG-UHFFFAOYSA-N; LMFA08030002; AN-38291; N-Butyryl-DL-homoserine lactone, &gt
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 443433
TTD: D0D3VA
 Compound Name WX-UK1 Discontinued in Phase 1/2 [15]
Synonyms
UKI-1; UNII-00LOF6890B; CHEMBL107955; 00LOF6890B; 220355-63-5; Wx-uk1 free base; compound 2r-L; GTPL6498; BDBM23891; 3-amidinophenylalanine deriv., 35; ZINC4426028; AKOS030526723; CS-5726; HY-100415; 1-Piperazinecarboxylic acid, 4-((2S)-3-(3-(aminoiminomethyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, ethyl ester; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-{[2,4,6
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 960 nM
External Link
CID: 9895194
TTD: D08INO
 Compound Name B-428 Terminated [16]
MOA Inhibitor
Activity Ki = 79.43 nM
External Link
CID: 1747
TTD: D0K1PR
 Compound Name UPA-targeted oncolytic Sendai virus Investigative [5]
Synonyms
BioKnife; RSeV/Fct14(uPA2)dM; UPA-targeted oncolytic Sendai virus, DNAVEC
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D00LDI
 Compound Name CRA_10655 Investigative [17]
Synonyms
AC1O4QGF
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 220 nM
External Link
CID: 447480
TTD: D01LCS
DrugBank: DB02526
 Compound Name 5-Methylsulfanyl-thiophene-2-carboxamidine Investigative [18]
Synonyms
CHEMBL28890; 2-Thiophenecarboximidamide, 5-(methylthio)-; SCHEMBL5982145; AXSQTCBARFBKPH-UHFFFAOYSA-N; BDBM50099912; 5-methylthiothiophene-2-carboxamidine
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 6000 nM
External Link
CID: 10313318
TTD: D02XJW
 Compound Name ATN-658 Investigative [5]
Synonyms
ATN-291; ATN-292; HuATN-658; UPA mAbs, Attenuon; MAb (urokinase plasminogen activator system), Attenuon/Kyowa Hakko Kirin
    Click to Show/Hide
MOA Activator
External Link
TTD: D03BWQ
 Compound Name (2R)-1-(2,6-dimethylphenoxy)propan-2-amine Investigative [17]
Synonyms
94991-73-8; (R)-1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-, (2R)-; CHEMBL147507; zlchem 1301; (R)-MEXILETINE; (R)-(-)-Mexiletine; AC1L47IL; SCHEMBL16082; BIDD:GT0498; ZINC20257; ZLE0076; DTXSID50241709; BDBM50135883; AKOS017529564; DB07129; AJ-08428; KB-209407; (2R)-1-(2,6-dimethylphenoxy)-2-propanamine; A821017; (R)-2-(2,6-Dimethyl-phenoxy)-1-methyl-ethylamine; UNII-1U511HHV4Z component VLPIATFUUWWMKC-SNVBAGLBSA-N
    Click to Show/Hide
MOA Inhibitor
Activity IC50 > 1000000 nM
External Link
CID: 180621
TTD: D03NLL
DrugBank: DB07129
 Compound Name B-623 Investigative [19]
Synonyms
149732-37-6
    Click to Show/Hide
MOA Modulator
Activity Ki = 530 nM
External Link
CID: 9820186
TTD: D05DNW
 Compound Name 4-chloro-1-guanidino-7-isoquinolinesulphonamide Investigative [20]
Synonyms
223671-02-1; 1-GUANIDINO-4-CHLORO-7-SULFAMOYL-ISOQUINOLINE; 2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine; CHEMBL227782; SCHEMBL6437735; CTK4E9305; BDBM16132; DTXSID90586545; FXVHAOFNNRNCRJ-UHFFFAOYSA-N; AKOS015966420; 1-guanidino-7-sulfonamidoisoquinoline 6; ACM223671021; 4-chloro-1-guanidino-7-sulphamoylisoquinoline
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 140 nM
External Link
CID: 16658353
TTD: D06CJP
 Compound Name 2-Amino-5-Hydroxy-Benzimidazole Investigative [21]
MOA Inhibitor
Activity IC50 = 200000 nM
External Link
CID: 162636
TTD: D09KKF
DrugBank: DB03729
 Compound Name 6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine Investigative [21]
Synonyms
CHEMBL104937; 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE; 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide; 1owe; uPa_7; AC1L9L6A; SCHEMBL4324160; ZINC2047486; BDBM50138670; 6-carbamimidoyl-N-phenyl-2-naphthamide; DB01977; 6-Carbamimidoyl-naphthalene-2-carboxylic acid phenylamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 630 nM
External Link
CID: 447732
TTD: D0A8WP
DrugBank: DB01977
 Compound Name Thieno[2,3-B]Pyridine-2-Carboxamidine Investigative [17]
Synonyms
amino(thieno[2,3-b]pyridin-2-yl)methaniminium; [amino(thieno[2,3-b]pyridin-2-yl)methylidene]azanium; AC1L1KCT; BDBM14171; CTK7D1810; APC-7538
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5438
TTD: D0B1AK
DrugBank: DB03876
 Compound Name Recombinant human pro-urokinase Investigative [5]
Synonyms
Recombinant human pro-urokinase (myocardial infarction)
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0D1TX
 Compound Name N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea Investigative [21]
Synonyms
AGB; 1ejn; AC1L1HTN; SCHEMBL4328331; WX293T; SCHEMBL14524522; CTK7G4253; BDBM16176; WX-293T; DB03782; 3-adamantan-1-yl-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(1-adamantyl)-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(adamantan-1-yl)-1-[(4-carbamimidamidophenyl)methyl]urea; 1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea; 1-{4-[(diaminomethylidene)amino]benzyl}-3-tricyclo[3.3.1.13,7]dec-1-ylurea
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 4286
TTD: D0EV6B
DrugBank: DB03782
 Compound Name (4-guanidino-benzyl)-carbamic acid benzyl ester Investigative [22]
Synonyms
CHEMBL391969
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 16000 nM
External Link
CID: 44436702
TTD: D0F6EZ
 Compound Name 1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine Investigative [17]
Synonyms
SCHEMBL20553177; DB07122
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16758228
TTD: D0ZM9M
DrugBank: DB07122
 Compound Name 4-methoxy-N'-(2-phenylacetyl)benzohydrazide Investigative [23]
Synonyms
4-methoxy-N'-(phenylacetyl)benzohydrazide; benzohydrazide, 15; AC1LEZHC; CHEMBL244921; ARONIS002261; BDBM23731; ZINC68809; KS-00003VJE; MolPort-000-681-545; STK056698; AKOS000492246; MCULE-6943344531; ST040019; 4-methoxy-N -(phenylacetyl)benzohydrazide; KB-115318; 4-methoxy-N''-(2-phenylacetyl)benzohydrazide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2500 nM
External Link
CID: 695069
TTD: D02AKP
 Compound Name ATF-HI-8 Investigative [24]
Synonyms
urokinase/urinary trypsin inhibitor chimera, Nissin/Hamamatsu University
    Click to Show/Hide
MOA Modulator
External Link
TTD: D05ABK
 Compound Name 1-guanidino-7-isoquinolinesulphonamide Investigative [20]
Synonyms
SCHEMBL6436143; CHEMBL227583; 7-Isoquinolinesulfonamide, 1-[(aminoiminomethyl)amino]-; BDBM16130; NRVVFOKWKSWIIV-UHFFFAOYSA-N; 1-Guanidino-7-sulphamoylisoquinoline; 1-guanidino-7-sulfonamidoisoquinoline 4; 2-(7-sulfamoylisoquinolin-1-yl)guanidine
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 280 nM
External Link
CID: 16658352
TTD: D0K4PK
 Compound Name CRA_8696 Investigative [17]
Synonyms
AC1O4QGN
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 8 nM
External Link
CID: 447476
TTD: D0K7YL
DrugBank: DB03159
 Compound Name 1-guanidino-N-phenyl-7-isoquinolinesulphonamide Investigative [20]
Synonyms
SCHEMBL6435184; CHEMBL227781; BDBM16131; NNEJXIJKGKRBBF-UHFFFAOYSA-N; 1-guanidino-7-sulfonamidoisoquinoline 5; 1-guanidino-7-phenylsulphamoylisoquinoline
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 160 nM
External Link
CID: 16658631
TTD: D00PEJ
 Compound Name (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone Investigative [23]
Synonyms
BAS 02052986; AC1LDSC0; N-Benzoylpyrazole deriv., 20; CHEMBL244072; ZINC37170; BDBM23712; MolPort-001-971-782; AKOS000577347; 2-methylphenyl 4-nitropyrazolyl ketone; MCULE-4726161589; ST033205; (4-Nitro-pyrazol-1-yl)-o-tolyl-methanone; (2-methylphenyl)-(4-nitropyrazol-1-yl)methanone
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1300 nM
External Link
CID: 674641
TTD: D00WFQ
 Compound Name 4-iodobenzo[b]thiophene 2-carboxamidine Investigative [25]
Synonyms
amino(4-iodo-1-benzothiophen-2-yl)methaniminium; ESI; AC1L1C5C; CTK7C3490; BDBM14169; APC-6860; CRA-6860; DB03136; [amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 1746
TTD: D05MJU
DrugBank: DB03136
 Compound Name (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone Investigative [23]
Synonyms
BAS 02052938; AC1LDSCA; N-Benzoylpyrazole deriv., 5; 4-nitropyrazolyl phenyl ketone; CHEMBL244908; 1-benzoyl-4-nitro-1H-pyrazole; ZINC37183; BDBM23703; AKOS000577075; (4-nitropyrazol-1-yl)-phenylmethanone; MCULE-3158742884; ST033219; (4-Nitro-pyrazol-1-yl)-phenyl-methanone; SR-01000312627
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 18200 nM
External Link
CID: 674651
TTD: D06LPR
 Compound Name 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine Investigative [26]
Synonyms
(S)-3-(3-(4-(2-GUANIDINOETHYL)PIPERIDIN-1-YL)-2-(NAPHTHALENE-2-SULFONAMIDO)-3-OXOPROPYL)BENZIMIDAMIDE; 2gv6; AC1OA9XW; CHEMBL210771; SCHEMBL12960819; BDBM23902; 3-amidinophenylalanine deriv., 8; 3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-(naphthalene-2-sulfonamido)-3-oxopropyl]benzene-1-carboximidamide; 3-{(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl}benzenecarboximidamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1300 nM
External Link
CID: 6852210
TTD: D0SP2I
 Compound Name (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative [23]
Synonyms
AC1LDSCF; N-Benzoylpyrazole deriv., 7; CHEMBL244909; ZINC37188; BDBM23705; MolPort-002-174-815; AKOS000576906; 4-bromopyrazolyl 4-methylphenyl ketone; MCULE-8194486011; ST033225; AB00100488-01; (4-bromopyrazol-1-yl)-(4-methylphenyl)methanone; SR-01000521427; SR-01000521427-1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1700 nM
External Link
CID: 674656
TTD: D05ZIP
 Compound Name Benzamidine Investigative [21]
Synonyms
Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 180000 nM
External Link
CID: 2332
TTD: D07SFI
 Compound Name (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone Investigative [23]
Synonyms
(4-methylphenyl)(3-nitro-1H-pyrazol-1-yl)methanone; AC1LF99H; N-Benzoylpyrazole deriv., 18; CHEMBL244939; ZINC78678; BDBM23710; A2012/0084499; MolPort-002-705-255; STK760276; AKOS001746005; 4-methylphenyl 3-nitropyrazolyl ketone; MCULE-9242110239; ST073763; (4-methylphenyl)-(3-nitropyrazol-1-yl)methanone; SR-01000524341; 1-[(4-methylphenyl)carbonyl]-3-nitro-1H-pyrazole
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3100 nM
External Link
CID: 699665
TTD: D08OCS
 Compound Name 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide Investigative [23]
Synonyms
AC1LERN1; TimTec1_001906; Oprea1_174326; N-Benzoylpyrazole deriv., 6; CHEMBL388239; BDBM23704; MolPort-001-664-680; ZINC115253; HMS1539G14; STK398485; AKOS003748858; MCULE-1390939767; 1-benzoyl-N-phenylpyrazole-3-carboxamide; ST025783; N-phenyl[1-(phenylcarbonyl)pyrazol-3-yl]carboxamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1500 nM
External Link
CID: 716930
TTD: D0IU5E
 Compound Name (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone Investigative [23]
Synonyms
AC1LDSBN; BAS 02052919; N-Benzoylpyrazole deriv., 8; CHEMBL244917; ZINC37156; BDBM23706; MolPort-001-906-669; 3,4-dichlorophenyl pyrazolyl ketone; STK044137; AKOS000577014; MCULE-6190861509; ST033189; (3,4-dichlorophenyl)-pyrazol-1-ylmethanone; (3,4-Dichloro-phenyl)-pyrazol-1-yl-methanone; 1-[(3,4-dichlorophenyl)carbonyl]-1H-pyrazole; SR-01000521426; SR-01000521426-1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2600 nM
External Link
CID: 674628
TTD: D0X1OY
 Compound Name 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine Investigative [27]
Synonyms
amino[2-(2-hydroxyphenyl)-1H-indol-5-yl]methaniminium; AC1L1BMI; BDBM13942; CTK8A0256; APC-8328; DB02463; [amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 1507
TTD: D08OLP
DrugBank: DB02463
 Compound Name Fucose Investigative [21]
Synonyms
L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 17106
TTD: D0G6XS
2B91: Colorectal cancer 25 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Retifanlimab Approved [28]
Synonyms
INCMGA0012; Retifanlimab
    Click to Show/Hide
External Link
TTD: D0PG5O
 Compound Name Aflibercept Approved [29]
Synonyms
Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
    Click to Show/Hide
External Link
TTD: D0C9ET
 Compound Name Regorafenib Approved [30]
Synonyms
755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
    Click to Show/Hide
External Link
CID: 11167602
TTD: D09GDD
DrugBank: DB08896
 Compound Name Bevacizumab Approved [31]
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
External Link
TTD: D04KBL
 Compound Name SYM-004 Phase 3 [31]
Synonyms
Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
    Click to Show/Hide
External Link
TTD: D0CR8H
 Compound Name Bevacizumab + Erlotinib Phase 3 [32]
External Link
TTD: D09BKY
 Compound Name CPI-613 Phase 3 [31]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Bevacizumab Approved [29]
External Link
TTD: D0FX3U
 Compound Name AlloStim Phase 2/3 [33]
Synonyms
AlloStim (TN)
    Click to Show/Hide
External Link
TTD: D0B3CC
 Compound Name Sibrotuzumab Phase 2 [34]
External Link
TTD: DVX3H0
 Compound Name CV301 Phase 2 [35]
External Link
TTD: D9LT5G
 Compound Name Efatutazone Phase 2 [36]
Synonyms
Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
External Link
CID: 9832447
TTD: D0Y8NZ
DrugBank: DB11894
 Compound Name LOR-2040 Phase 2 [37]
External Link
TTD: D0I7NG
 Compound Name RG7221 Phase 2 [38]
External Link
TTD: D06FTM
 Compound Name PEG-SN38 Phase 2 [39]
Synonyms
EZN-2208
    Click to Show/Hide
External Link
CID: 59443782
TTD: D05UFP
 Compound Name MEGF0444A Phase 2 [40]
External Link
TTD: D01LES
 Compound Name Encapsulated cell therapy Phase 1/2 [41]
External Link
TTD: D0XY8C
 Compound Name AB928 Phase 1/2 [42]
External Link
CID: 135242184
TTD: D04UBI
 Compound Name MGD007 Phase 1 [38]
External Link
TTD: D00PEN
 Compound Name BNC-101 Phase 1 [43]
External Link
TTD: DD6AZ5
 Compound Name Navicixizumab Phase 1 [31]
External Link
TTD: D00IVN
 Compound Name RG7160 Discontinued in Phase 2 [44]
External Link
TTD: D0E2CQ
 Compound Name Nimesulide Terminated [45]
Synonyms
51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
    Click to Show/Hide
External Link
CID: 4495
TTD: D0C0JT
DrugBank: DB04743
 Compound Name Saracatinib Phase 2 [46]
External Link
CID: 10302451
TTD: D05YTN
DrugBank: DB11805
 Compound Name G3139 + Irinotecan Investigative [47]
External Link
CID: 91865905
TTD: D05IAN
References
Ref 1 LINC01605, regulated by the EP300-SMYD2 complex, potentiates the binding between METTL3 and SPTBN2 in colorectal cancer. Cancer Cell Int. 2021 Sep 20;21(1):504. doi: 10.1186/s12935-021-02180-8.
Ref 2 METTL3 promotes colorectal cancer metastasis by stabilizing PLAU mRNA in an m6A-dependent manner. Biochem Biophys Res Commun. 2022 Jul 23;614:9-16. doi: 10.1016/j.bbrc.2022.04.141. Epub 2022 May 6.
Ref 3 Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11.
Ref 4 Clinical pipeline report, company report or official report of FORMA Therapeutics.
Ref 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
Ref 6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 7 Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6. doi: 10.1093/jnci/87.10.751.
Ref 8 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. doi: 10.1517/14728214.11.1.75.
Ref 9 Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70. doi: 10.1038/bjc.2013.62. Epub 2013 Feb 14.
Ref 10 Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
Ref 11 Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
Ref 12 Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6. doi: 10.1021/jm701359z. Epub 2007 Dec 29.
Ref 13 Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30. doi: 10.1016/j.bmcl.2004.03.094.
Ref 14 Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41. doi: 10.1002/(sici)1097-0320(20000501)40:1<32::aid-cyto5>3.0.co;2-z.
Ref 15 Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24. doi: 10.1002/ijc.20192.
Ref 16 Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Adv Exp Med Biol. 2000;477:331-41. doi: 10.1007/0-306-46826-3_36.
Ref 17 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 18 Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors. Bioorg Med Chem Lett. 2002 Feb 11;12(3):491-5. doi: 10.1016/s0960-894x(01)00787-9.
Ref 19 Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep. 1999 May-Jun;6(3):523-6. doi: 10.3892/or.6.3.523.
Ref 20 Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51. doi: 10.1021/jm061066t. Epub 2007 Apr 21.
Ref 21 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 22 Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. J Med Chem. 2007 Dec 27;50(26):6638-46. doi: 10.1021/jm700962j. Epub 2007 Dec 1.
Ref 23 N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. doi: 10.1021/jm070600+. Epub 2007 Sep 12.
Ref 24 Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem. 1995 Apr 7;270(14):8361-6. doi: 10.1074/jbc.270.14.8361.
Ref 25 Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol. 2000 Apr;7(4):299-312. doi: 10.1016/s1074-5521(00)00104-6.
Ref 26 Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26. doi: 10.1021/jm051272l.
Ref 27 Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. J Med Chem. 2001 Aug 16;44(17):2753-71. doi: 10.1021/jm0100638.
Ref 28 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 29 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
Ref 31 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 32 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Ref 33 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 34 ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 35 ClinicalTrials.gov (NCT03547999) A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC. U.S. National Institutes of Health.
Ref 36 ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 38 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 39 ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 40 ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 41 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 42 ClinicalTrials.gov (NCT04660812) An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 43 ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 44 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
Ref 45 Clinical pipeline report, company report or official report of Genentech (2011).
Ref 46 Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
Ref 47 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.